Bartosz Hudzik/LinkedIn
May 23, 2026, 16:42
Bartosz Hudzik: Bleeding Risk Alone Should Not Determine Treatment Intensity
Bartosz Hudzik, Associate Profesor at Medical University of Silesia, shared his post a post on X, adding:
“HBR has become synonymous with antithrombotic de-escalation.
Yet bleeding risk alone should not determine treatment intensity.
Many AF, MI, PCI patients classified as HBR remain ischemic-risk dominant, underscoring the need for personalized rather than algorithmic therapy.”
Bartosz Hudzik shared a post on X:
“At EuroPCR 2026, we show that many HBR, AF, MI, PCI patients remain ischemic-risk dominant despite high bleeding risk.
In selected patients, triple antithrombotic therapy may still provide net clinical benefit”
Other posts featuring Bartosz Hudzik on Hemostasis Today.
-
Aug 21, 2026, 21:58Toby Richards: WEHI Trial Solidifies IV Iron as Third-Trimester Standard
-
Aug 21, 2026, 21:51Mehak Trehan: From Reading the Chapter to Writing One
-
Aug 21, 2026, 21:38Ann Reilly: Navigating Postoperative vs. Acute Blood Loss Anemia – A CDI Case Study
-
Aug 21, 2026, 21:29Merlin Crossley: Atomic Precision in Sickle Cell Care – Structural Targeting for Fetal Globin Reactivation
-
Aug 21, 2026, 19:09Aphisit Thongthaisin: Admitted to Sorbonne University’s T2H University Diploma for 2026/2027
-
Aug 21, 2026, 19:07José Luis Ferreiro Gutiérrez: Proud to Be Elected Chairperson-Elect of the ESC Working Group on Thrombosis
-
Aug 21, 2026, 19:00Manuel Monreal: New RIETE Registry Data on VTE Recurrence and Bleeding During Anticoagulation
-
Aug 21, 2026, 18:39Ronak H. Mistry: Updated ASH ITP Guidelines Bring New Guidance for Managing ITP
-
Aug 21, 2026, 18:22Ahmed Bennis: NOAC Use Is Associated With Slower Cognitive Decline in AF and Alzheimer’s Disease